On September 30, Hong Kong pharmaceutical stocks continued their independent rally, bucking the broader market trend. AI drug discovery led the charge, with XtalPi Holdings surging more than 4%, while upstream service providers collectively strengthened. GenScript Biotech skyrocketed over 9% to hit another all-time high, and Joinn Laboratories gained more than 7%. The underlying index of Hang Seng Healthcare ETF Huabao (159137), which has nearly 70% exposure to AI drug discovery, briefly climbed over 2.6%.

The innovative drug sector also remained active, with the underlying index of Hang Seng Innovative Drug ETF Huabao (520880) holding 100% innovative drug exposure and rising over 2.3% during intraday trading. Among constituent stocks, CanSino Biologics soared 18%, AI drug discovery concept Insilico Medicine gained over 7%, and Everest Medicines rose more than 4%.

On the news front, foreign investment giant FMR LLC, the parent company of Fidelity Investments, increased its stake in GenScript Biotech by 6.846 million shares on September 24 at HK$40.2549 per share, with a total transaction value of approximately HK$276 million, signaling confidence in the company's outlook. On September 23, Anthropic revealed that Claude autonomously discovered a previously uncharacterized ART enzyme system: approximately 950 agents searched over 200,000 types of reverse transcriptase, screened 3,500 candidates, and identified a novel enzyme system similar to CRISPR within 21 hours; its function is still being validated. Analysts noted that this is not simply "AI-assisted experimentation," but rather agents autonomously completing literature review, data search, hypothesis generation, candidate screening, and experimental validation, marking AI's evolution from a "tool" to a "scientific researcher."

CITIC Securities believes that AI4S is entering a new phase from "improving R&D efficiency" to "autonomously generating scientific hypotheses," further highlighting the value of the dry-wet closed loop. With AI drug discovery gaining strong momentum, how can investors efficiently position themselves? Two T+0 trading tools are worth watching: Hang Seng Healthcare ETF Huabao (159137), whose underlying index heavily weights the innovative drug industry chain with nearly 70% AI drug discovery exposure and over 50% CXO exposure, with an off-exchange feeder fund coded 026922; and Hang Seng Innovative Drug ETF Huabao (520880), whose underlying index holds 100% exposure to innovative drug R&D companies, with 70% of positions concentrated in innovative drug R&D leaders, with an off-exchange feeder fund coded 025221.

【Data Sources】Public information from Shanghai, Hong Kong, and Shenzhen stock exchanges, China Securities Index Company, Hang Seng Index Company, etc. Weight data as of August 31, 2026.

【Institutional View】CITIC Securities, September 29, 2026, "AI Drug Discovery Enters New Stage of Autonomous Scientific Discovery."

【Notes on "AI Drug Discovery Exposure" and "CXO Exposure"】The Hang Seng Healthcare Theme Index tracked by Hang Seng Healthcare ETF Huabao covers 17 AI drug discovery-related constituent stocks, including pure AI drug discovery platforms, AI+CRO companies, and innovative drug companies deploying AI drug discovery, with a combined weighting of 69.52%, of which CXO companies account for 55%.

【Fund Fee Rates】ETF funds do not charge sales service fees. When investors subscribe or redeem fund shares, the subscription and redemption agency broker may charge a commission of no more than 0.5%, which includes fees charged by stock exchanges, registration institutions, and other related parties. Fund fee rates are detailed in each fund's legal documents.

【Special Notice】The risk rating assessed by the fund manager for Hang Seng Healthcare ETF Huabao and its feeder fund, as well as Hang Seng Innovative Drug ETF Huabao and its feeder fund, is R4-Medium-High Risk, suitable for aggressive (C4) and above investors.

【Risk Disclosure】The index constituent stocks mentioned in this article are for display purposes only. Individual stock descriptions do not constitute any form of investment advice and do not represent the holdings or trading activities of any fund under the manager. Any information appearing in this article (including but not limited to individual stocks, comments, predictions, charts, indicators, theories, and any form of expression) is for reference only, and investors must be responsible for their own independent investment decisions. Additionally, any views, analyses, and predictions in this article do not constitute any form of investment advice to readers, nor shall the author bear any direct or indirect liability arising from the use of the content herein. The performance of other funds managed by the fund manager does not guarantee fund performance. Past performance of a fund is not indicative of future results. Fund investment involves risks.

MACD golden cross signals have formed; these stocks are performing well!